[1]Shun Lu , et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC. Analyses of CNS and distant progression from the phase lll LAURA study . 2024 ESMO, 1241MO.
[2]Kato T, Casarini I, Cobo M,et al. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. Lung Cancer. 2024 Jan;187:107414.[3]Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC[J]. New England Journal of Medicine, 2024, 391(5): 588-597.